I can't seem to find a definitive answer on the internet and it is so hard to get hold of the doctor who prescribed it. A medication's half-life is the time it takes for the plasma concentration of a drug to reach half of its original concentration.
More simply put, the half-life of a drug is how long it takes for half of it to be eliminated from the bloodstream. The half-life of Singulair montelukast is approximately 5. The full amount of medication will be out of your system in 30 hours at the most. Lori Poulin, PharmD Q: I currently take Singulair 10 mg. Is there another medicine that would be comparable that would cost less? Brand name prescription drugs are protected under patent. When the patent expires, other drug companies can start manufacturing and selling a generic form of the drug.
The patent for Singulair montelukast will not expire until August ; therefore, no generic form is currently available. Other medications in the same class called leukotriene inhibitors antagonists include Accolate zafirlukast and Zyflo zileuton. However, the choice of medication will depend on your specific circumstances. For more detailed information, consult with your physician or pharmacist for guidance based on your specific condition and current medications.
I have asthma and stopped taking Singulair yesterday. I can't seem to find a definitive answer on the Internet, and it's difficult to contact the doctor who prescribed it.
Can Singulair be used for capsular contracture associated with breast implants? Singulair montelukast is a leukotriene inhibitor that is used for the treatment of asthma and allergies. Leukotrienes are chemicals in the body that are released as part of the allergic response. Capsular contracture is an abnormal response of the immune system to foreign materials, including breast implants.
The treatment of capsular contracture with leukotriene inhibitors including Singulair and Accolate [zafirlukast] has been reported in the medical literature. Anecdotal reports have shown that zafirlukast and montelukast may reverse capsular contracture. These reports have not been confirmed in scientific studies and this use of leukotriene inhibitors is not approved by the US Food and Drug Administration. For more information, please contact your healthcare provider. Is it possible to be allergic to Singulair?
It is possible for a person to be allergic to Singulair montelukast. Get emergency medical help if you have any of these signs of an allergic reaction: Will Singulair help my wheezing and shortness of breath? I take Warfarin, glyburide, atenolol, and Cozaar. Singulair is used to prevent asthma attacks and to relieve allergies.
One thing to keep in mind is that Singulair may take a couple of weeks before any benefits can be seen. Also, Singulair does not have any interactions with any of your current medications. Megan Uehara, PharmD Q: My allergies are mainly from mid-August to the first snow. I know I'm severely alregic to mold.
Singulair seems to be the best medication for me. Singulair montelukast is classified as a leukotriene receptor antagonist. Unfortunately, there are no over-the-counter products that fall into this same class of medications.
Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.
Characteristics in patients No dosage adjustment is necessary for the elderly or mild to moderate hepatic insufficiency. Studies in patients with renal impairment have not been undertaken. Because montelukast and its metabolites are eliminated by the biliary route, no dose adjustment is anticipated to be necessary in patients with renal impairment.
With high doses of montelukast and fold the recommended adult dose , a decrease in plasma theophylline concentration was observed. This effect was not seen at the recommended dose of 10 mg once daily. The signs of toxicity in animals were increased excretion of saliva, gastrointestinal symptoms, loose stools and ion imbalance. In animal studies, montelukast did not affect fertility or reproductive performance at systemic exposure exceeding the clinical systemic exposure by greater than fold.
No abnormalities were seen in rats. Montelukast has been shown to cross the placental barrier and is excreted in breast milk of animals.
This dose is equivalent to 25, times the recommended daily adult human dose based on an adult patient weight of 50 kg. Montelukast was neither mutagenic in in vitro and in vivo tests nor tumorigenic in rodent species. Always speak with your doctor or pharmacist about dosages that are right for you. Take as directed Montelukast oral tablet is used for long-term treatment. You increase your risk of more frequent and more severe asthma attacks.
Asthma that is not treated can lead to increased lung damage. If you have allergies, their symptoms may not be reduced. These eicosanoids bind to cysteinyl leukotriene CysLT receptors. The CysLT type-1 CysLT1 receptor is found in the human airway including airway smooth muscle cells and airway macrophages and on other pro-inflammatory cells including eosinophils and certain myeloid stem cells. CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis.
In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis.
Pharmacodynamics Montelukast causes inhibition of airway cysteinyl leukotriene receptors as demonstrated by the ability to inhibit bronchoconstriction due to inhaled LTD4 in asthmatics. The effect of Singulair on eosinophils in the peripheral blood was examined in clinical trials. In patients with seasonal allergic rhinitis aged 15 years and older who received Singulair, a mean increase of 0.
The relationship between these observations and the clinical benefits of montelukast noted in the clinical trials is not known [see Clinical Studies 14 ]. Pharmacokinetics Absorption Montelukast is rapidly absorbed following oral administration. After administration of the mg film-coated tablet to fasted adults, the mean peak montelukast plasma concentration Cmax is achieved in 3 to 4 hours Tmax.
The oral bioavailability and Cmax are not influenced by a standard meal in the morning. For the 5-mg chewable tablet, the mean Cmax is achieved in 2 to 2. For the 4-mg chewable tablet, the mean Cmax is achieved 2 hours after administration in pediatric patients 2 to 5 years of age in the fasted state. The 4-mg oral granule formulation is bioequivalent to the 4-mg chewable tablet when administered to adults in the fasted state.
The co-administration of the oral granule formulation with applesauce did not have a clinically significant effect on the pharmacokinetics of montelukast.
The safety and efficacy of Singulair in patients with asthma were demonstrated in clinical trials in which the mg film-coated tablet and 5-mg chewable tablet formulations were administered in the evening without regard to the time of food ingestion. The safety of Singulair in patients with asthma was also demonstrated in clinical trials in which the 4-mg chewable tablet and 4-mg oral granule formulations were administered in the evening without regard to the time of food ingestion.
The safety and efficacy of Singulair in patients with seasonal allergic rhinitis were demonstrated in clinical trials in which the mg film-coated tablet was administered in the morning or evening without regard to the time of food ingestion.
The comparative pharmacokinetics of montelukast when administered as two 5-mg chewable tablets versus one mg film-coated tablet have not been evaluated. The steady state volume of distribution of montelukast averages 8 to 11 liters. Studies in rats with radiolabeled montelukast indicate minimal distribution across the blood-brain barrier.
In addition, concentrations of radiolabeled material at 24 hours postdose were minimal in all other tissues. Efficacy has been demonstrated for asthma when montelukast was administered in the evening without regard to time of food ingestion. Safety and efficacy in patients younger than 6 years of age have not been established. Efficacy was demonstrated for seasonal allergic rhinitis when montelukast was administered in the morning or the evening without regard to time of food ingestion.
The safety of SINGULAIR in patients with asthma was also demonstrated in clinical trials in which the 4-mg chewable tablet and 4-mg oral granule formulations were administered in the evening without regard to the time of food ingestion. The safety and efficacy of SINGULAIR in patients with seasonal allergic rhinitis were demonstrated in clinical trials in which the mg film-coated tablet was administered in the morning or evening without regard to the time of food ingestion.
The comparative pharmacokinetics of montelukast when administered as two 5-mg chewable tablets versus one mg film-coated tablet have not been evaluated. The steady state volume of distribution of montelukast averages 8 to 11 liters.
Studies in rats with radiolabeled montelukast indicate minimal distribution across the blood-brain barrier. In addition, concentrations of radiolabeled material at 24 hours postdose were minimal in all other tissues. Metabolism Montelukast is extensively metabolized. In studies with therapeutic doses, plasma concentrations of metabolites of montelukast are undetectable at steady state in adults and pediatric patients.
In vitro studies using human liver microsomes indicate that CYP3A4, 2C8, and 2C9 are involved in the metabolism of montelukast. At clinically relevant concentrations, 2C8 appears to play a major role in the metabolism of montelukast.
Coupled with estimates of montelukast oral bioavailability, this indicates that montelukast and its metabolites are excreted almost exclusively via the bile.
In several studies, the mean plasma half-life of montelukast ranged from 2. The pharmacokinetics of montelukast are nearly linear for oral doses up to 50 mg. Special Populations Hepatic Insufficiency: The elimination of montelukast was slightly prolonged compared with that in healthy subjects mean half-life, 7. No dosage adjustment is required in patients with mild-to-moderate hepatic insufficiency. Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast were not evaluated in patients with renal insufficiency.
No dosage adjustment is recommended in these patients. The pharmacokinetics of montelukast are similar in males and females.
The CysLT type-1 CysLT1 receptor is found in the human airway including airway smooth muscle indications and airway macrophages and on other pro-inflammatory cells 4mg eosinophils and certain myeloid stem cells. Adults and Adolescents 15 Years of Age and Older with Seasonal Allergic Rhinitis Singulair has been 4mg for safety in adult and adolescent patients 15 years of age and older in clinical trials. Always speak with your indication or pharmacist about dosages that are right for you, singulair 4mg indication. And exercise-related breathing problems may not be controlled. At high concentrations in vitro, clopidogrel also inhibits the activity of CYP2C9. For adults and adolescents 15 years of age and older: Unfortunately, there are no over-the-counter products singulair fall into this same class of medications. Studies in rats with radiolabeled montelukast indicate minimal distribution across the blood-brain barrier. Defined for each Adverse Reaction by the incidence reported in the clinical trials data singulair Patti Brown, singulair 4mg indication, PharmD Q: There have been reports of acute overdose in post-marketing experience and clinical studies with montelukast.
© Copyright 2017 Singulair 4mg indication *** www.get-club.net.